Medical Genetics · Mitochondrial Disease Associated With the MT-TL1 m.3243A>G Variant

The Genetics: MT-TL1 and the m.3243A>G Variant

At a Glance

The MT-TL1 m.3243A>G variant can reduce the energy cells make, but symptoms vary because the amount of altered mitochondrial DNA differs across tissues. It is usually passed through the mother, and test results help guide care without precisely predicting future health.

The genetics of mitochondrial disease can be confusing because they don’t follow the “dominant” or “recessive” patterns many of us learned in school. When you are diagnosed with the m.3243A>G variant in the MT-TL1 gene, your diagnosis is based on a specific change in the DNA inside your mitochondria—the power plants of your cells ^[1].

Maternal Inheritance and the “Bottleneck”

Most of your DNA is found in the nucleus of your cells and comes from both parents. However, mitochondrial DNA (mtDNA) is almost always inherited exclusively from your mother ^[2].

During the development of a mother’s egg cells, the body goes through a “genetic bottleneck.” This means only a small, random sample of the mother’s mitochondria is passed on to each egg ^[3].

Affected Women: A woman with a pathogenic mtDNA variant may pass it to each of her children. Because of the bottleneck, the level of the variant (and the resulting symptoms) can be highly unpredictable from one child to the next ^[2]^[4].
Affected Men: Men who carry an mtDNA variant generally do not pass it on to their children, as sperm do not typically contribute mitochondria to the embryo.

Because predicting a child’s severity from a parent’s variant level is extremely difficult, genetic counseling is highly recommended before making reproductive decisions or testing asymptomatic children. It is also important to note that an absent maternal family history does not rule out the diagnosis.

The Biological Mechanism: An Energy Crisis

The MT-TL1 gene provides instructions for making a specialized molecule called tRNA-Leu(UUR) ^[5]. Think of this molecule as a delivery truck that carries essential building blocks (amino acids) to the “factories” that build your cell’s energy-producing machinery.

When the m.3243A>G variant is present, it acts like a glitch in the delivery system:

Structural Instability: The tRNA molecule becomes unstable and can break down prematurely ^[5]^[6].
Assembly Failure: Because the delivery trucks are broken, your cells cannot properly build the proteins needed for oxidative phosphorylation—the process that turns oxygen and nutrients into energy (ATP) ^[7]^[8].
Fuel Shortage: Without enough ATP, high-energy organs like the heart, brain, and ears begin to struggle, leading to the symptoms associated with the condition ^[9]^[10].

What is Heteroplasmy?

One of the most critical terms to understand is heteroplasmy. Most genetic conditions are “all or nothing,” but mitochondrial variants are often a “mix” ^[11]. Inside a single cell, you have a population of healthy mitochondria and a population of variant ones living together ^[12]. Your heteroplasmy level is the proportion of mitochondria that carry the variant.

Why Tissue Choice Matters

Your heteroplasmy level is not the same in every part of your body. Different tissues have different “loads” of the variant ^[13]:

Blood: Heteroplasmy in the blood tends to be lower and decreases as you age ^[14]^[11]. For some older adults, the variant may be nearly invisible in a blood test even if they are quite ill.
Urine and Buccal Swabs: Urinary epithelial cells and buccal (cheek/saliva) samples may be useful because they can show higher levels, though results vary by laboratory assay ^[13]^[15].
Muscle: Muscle biopsy is invasive and modern diagnosis often avoids it; it is usually reserved only for clinically unresolved cases ^[14].

Does a Higher Percentage Mean Worse Symptoms?

In cohort studies, higher heteroplasmy levels are generally associated with an earlier onset of symptoms and a higher risk of complications like diabetes or hearing loss ^[16]^[15]. However, heteroplasmy is not a perfect predictor of your future and cannot be used as a personal clock ^[17].

Some people with high heteroplasmy levels in their blood remain relatively healthy, while others with low levels may experience significant challenges ^[18]^[4]. This is because your health is influenced by many other factors, including your mtDNA copy number (how many total mitochondria you have), your nuclear genes, and your lifestyle ^[17]^[19]. Doctors use heteroplasmy as one piece of the puzzle, but they focus much more on your actual symptoms and regular clinical screenings to guide your care ^[20].

Common questions in this guide

What does an m.3243A>G change in the MT-TL1 gene mean?

It means a change is present in mitochondrial DNA that can disrupt the cell’s energy-making system. Organs that need a lot of energy, including the heart, brain, and ears, may be affected, but symptoms and severity vary from person to person.

What is heteroplasmy, and why does it matter?

Heteroplasmy is the mix of healthy and variant mitochondria in a person’s cells. The percentage can differ between tissues and is linked at a group level with age at symptom onset and risks such as diabetes or hearing loss, but it cannot predict an individual’s future by itself.

Can this mitochondrial DNA variant be passed to children?

Mitochondrial DNA is almost always inherited from the mother. A woman with the variant may pass it to each child, but a genetic bottleneck makes the amount inherited and the symptoms difficult to predict; men who carry an mtDNA variant generally do not pass it on.

Why might a blood test show little or no m.3243A>G variant?

The amount of m.3243A>G in blood often decreases with age, so a blood result may not reflect levels in other tissues. Urine or cheek-cell testing may sometimes detect higher levels, although results vary by laboratory; muscle biopsy is invasive and is usually reserved for unresolved cases.

Does a higher heteroplasmy level mean my disease will be more severe?

Higher levels are generally associated with earlier symptoms and a greater risk of some complications in groups of patients. However, heteroplasmy is not a personal countdown: symptoms also depend on the tissue tested, mitochondrial DNA copy number, nuclear genes, lifestyle, and other factors.

Should my relatives or children have genetic testing?

Because the variant can be inherited through the maternal line and may cause few or no early symptoms, relatives and children may benefit from a personalized discussion with a genetics professional. Testing decisions should consider the person’s age, symptoms, family plans, and the tissue or test used.

Get notified when new evidence is published on Mitochondrial DNA-related cardiomyopathy and hearing loss.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (20)

1
Incidence and prevalence of mtDNA-related adult mitochondrial disease in Southwest Finland, 2009-2022: an observational, population-based study.
Martikainen MH, Majamaa K
BMJ neurology open 2024; (6(1)):e000546 doi:10.1136/bmjno-2023-000546.
PMID: 38361968
2
Mitochondrial DNA sequence characteristics modulate the size of the genetic bottleneck.
Wilson IJ, Carling PJ, Alston CL, et al.
Human molecular genetics 2016; (25(5)):1031-41 doi:10.1093/hmg/ddv626.
PMID: 26740552
3
Mutation-specific effects in germline transmission of pathogenic mtDNA variants.
Otten ABC, Sallevelt SCEH, Carling PJ, et al.
Human reproduction (Oxford, England) 2018; (33(7)):1331-1341 doi:10.1093/humrep/dey114.
PMID: 29850888
4
Heteroplasmy and phenotype spectrum of the mitochondrial tRNALeu (UUR) gene m.3243A>G mutation in seven Han Chinese families.
Liu G, Shen X, Sun Y, et al.
Journal of the neurological sciences 2020; (408()):116562 doi:10.1016/j.jns.2019.116562.
PMID: 31722256
5
Mitochondrial Mutation Leads to Cardiomyocyte Hypertrophy by Disruption of Mitochondria-Associated ER Membrane.
Yu M, Song M, Zhang M, et al.
Cell proliferation 2025; (58(7)):e70002 doi:10.1111/cpr.70002.
PMID: 39981966
6
Short peptides from leucyl-tRNA synthetase rescue disease-causing mitochondrial tRNA point mutations.
Perli E, Fiorillo A, Giordano C, et al.
Human molecular genetics 2016; (25(5)):903-15 doi:10.1093/hmg/ddv619.
PMID: 26721932
7
MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.
El-Hattab AW, Adesina AM, Jones J, Scaglia F
Molecular genetics and metabolism 2015; (116(1-2)):4-12.
PMID: 26095523
8
Exploring the Ability of LARS2 Carboxy-Terminal Domain in Rescuing the MELAS Phenotype.
Capriglia F, Rizzo F, Petrosillo G, et al.
Life (Basel, Switzerland) 2021; (11(7)) doi:10.3390/life11070674.
PMID: 34357047
9
Acute myocardial infarction in a patient with MELAS syndrome: a possible link?
Cosma J, Russo A, Schino S, et al.
Minerva cardiology and angiology 2023; (71(4)):374-380 doi:10.23736/S2724-5683.22.06021-5.
PMID: 35767235
10
Varied Responses to a High m.3243A>G Mutation Load and Respiratory Chain Dysfunction in Patient-Derived Cardiomyocytes.
Ryytty S, Modi SR, Naumenko N, et al.
Cells 2022; (11(16)) doi:10.3390/cells11162593.
PMID: 36010669
11
Droplet digital polymerase chain reaction to measure heteroplasmic m.3243A>G mitochondrial mutations.
Matsumoto S, Uchiumi T, Noda N, et al.
Laboratory medicine 2024; (55(2)):227-233 doi:10.1093/labmed/lmad063.
PMID: 37478467
12
Mitochondrial DNA mutation m.3243A>G is associated with altered mitochondrial function in peripheral blood mononuclear cells, with heteroplasmy levels and with clinical phenotypes.
Geng X, Zhang Y, Yan J, et al.
Diabetic medicine : a journal of the British Diabetic Association 2019; (36(6)):776-783 doi:10.1111/dme.13874.
PMID: 30536471
13
Non-invasive urinary heteroplasmy screening outperforms blood testing for certain mitochondrial DNA variants in mitochondrial disease patients.
Okazaki A, Yatsuka Y, Fushimi T, et al.
Molecular genetics and metabolism 2026; (148(4)):110198 doi:10.1016/j.ymgme.2026.110198.
PMID: 42424991
14
mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease.
Grady JP, Pickett SJ, Ng YS, et al.
EMBO molecular medicine 2018; (10(6)) doi:10.15252/emmm.201708262.
PMID: 29735722
15
Screening for Maternally Inherited Diabetes and Deafness in Large Cohorts of Hearing Impaired and Diabetic Patients.
Varga L, Borecka S, Skopkova M, et al.
Ear and hearing 2026; (47(3)):863-876 doi:10.1097/AUD.0000000000001780.
PMID: 41664274
16
Penetrance and expressivity of mitochondrial variants in a large clinically unselected population.
Cannon SJ, Hall T, Hawkes G, et al.
Human molecular genetics 2024; (33(5)):465-474 doi:10.1093/hmg/ddad194.
PMID: 37988592
17
Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors.
Pickett SJ, Grady JP, Ng YS, et al.
Annals of clinical and translational neurology 2018; (5(3)):333-345 doi:10.1002/acn3.532.
PMID: 29560378
18
Heteroplasmy and Copy Number in the Common m.3243A>G Mutation-A Post-Mortem Genotype-Phenotype Analysis.
Scholle LM, Zierz S, Mawrin C, et al.
Genes 2020; (11(2)) doi:10.3390/genes11020212.
PMID: 32085658
19
Impact of measuring heteroplasmy of a pathogenic mitochondrial DNA variant at the single-cell level in individuals with mitochondrial disease.
Imai-Okazaki A, Nitta KR, Yatsuka Y, et al.
Journal of inherited metabolic disease 2022; (45(6)):1143-1150 doi:10.1002/jimd.12547.
PMID: 36053827
20
Six-year prospective follow-up study in 151 carriers of the mitochondrial DNA 3243 A>G variant.
de Laat P, Rodenburg RR, Roeleveld N, et al.
Journal of medical genetics 2021; (58(1)):48-55 doi:10.1136/jmedgenet-2019-106800.
PMID: 32439810

This page explains the MT-TL1 m.3243A>G variant, inheritance, and heteroplasmy for informational purposes only and does not constitute medical advice. Your genetics team should interpret your results and guide testing, screening, and family-planning decisions.

Guide Contents